Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM

Diabetes

Volumn 46, Issue 8, 1997, Pages 1354-1359

  Lehto, Seppo ^a   Rönnemaa, Tapani ^b,c   Haffner, Steven M ^d   Pyörälä, Kalevi ^a   Kallio, Veikko ^c   Laakso, Markku ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

EID: 1842301672     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.8.1354     Document Type: Article

References (40)

1. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metabol Rev 3:463-524, 1987
2. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038, 1979
3. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. Br Med J 287:867-870, 1983
4. Stamler J, Vaccaro O, Neaton J, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434-444, 1993
5. Goldberg RB: Lipid disorders in diabetes. Diabetes Care 4:561-572, 1981
6. Howard BV, Savage BJ, Bennion LJ, Bennett PH: Lipoprotein composition in diabetes mellitus. Atherosclerosis 30:153-162, 1978
7. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyörälä K, Penttilä I: Serum lipids and lipoproteins in middle-aged non-insulin dependent diabetics. Atherosclerosis 56:271-281, 1985
8. Laakso M, Barrett-Connor E: Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis 9:665-672, 1989
9. Laakso M, Lento S, Penttilä I, Pyörälä K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88:1421-1430, 1993
10. Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
11. Laakso M, Rol̈nnemaa T, Pyörälä K, Kallio V, Puukka P, Penttilä I: Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland. Diabetes Care 11:449-463, 1988
12. Madsbad S, Alberti KG, Binder C, Bunin JM, Faber OK, Krarup T, Regeur L: Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 2:1257-1259, 1979
13. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
14. World Health Organization: Proposal for the Multinational Monitoring of Trends and Determinants in Cardiovascular Disease and Protocol (MONICA Project). Geneva, World Health Org., 1983 (WHO/MNC/82.1 Rev. 1)
15. Faber OK, Binder C: C-peptide response to glucagon: a test for the residual B-cell function in diabetes mellitus. Diabetes 26:605-610, 1977
16. Kostner G: Enzymatic determination of cholesterol in high density lipoprotein fractions prepared by polyanion precipitation. Clin Chem 22:695, 1976
17. Cox DR: Regression models and life-tables. J Roy Stat Soc 34:187-201, 1972
18. Laakso M, Rönnemaa T, Lento S, Puukka P, Kallio V, Pyörälä K: Does NIDDM increase the risk for coronary heart disease similarly in low and high risk populations? Diabetoloaia 38:487-493, 1995
19. National Cholesterol Education Program Expert Panel, National Heart, Lung and Blood Institute: Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 148:36-69, 1988
20. Pyörälä K, De Becker G, Graham I, Poole-Wilson P, Wood D on behalf of the Task Force: Prevention of coronary heart disease in clinical practise: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 110:121-161, 1994
21. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. AT Engl J Med 329:977-986, 1993
22. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
23. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
24. UK Prospective Study Group: UK Prospective Diabetes Study (UKPG). VIII. Study design, progress and performance. Diabetologia 34:877-890, 1991
25. Brownlee M: Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15:1835-1843, 1992
26. Lyons TJ: Lipoprotein glycation and its metabolic consequences. Diabetes (Suppl. 2):67-73, 1992
27. Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131-141, 1972
28. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G: Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease mortality in middle-aged population. Diabetologia 19:205-210, 1980
29. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care 2:154-160, 1979
30. Rönnemaa T, Laakso M, Pyörälä K, Kallio V, Puukka P: High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 11:80-90, 1991
31. Badimon JJ, Fuster V, Chesebro JH, Badimon L: Coronary atherosclerosis: a multifactorial disease. Circulation 87 (Suppl. 3):II3-II16, 1993
32. Colwell JA: Vascular thrombosis in type II diabetes (Editorial). Diabetes 42:8-11, 1993
33. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skoliuk E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:826-842, 1991
34. West KM, Ahuja MM, Bennett PH, Czyczk A, de Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K, Keen H, Krowlewski AS, Miki E, Schliack V, Teuscher A, Watkins P, Stober JA: The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 6:361-369, 1983
35. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warmet J, Claude JR, Rosselin GE: Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective study. Diabetologia 32:300-304, 1989
36. James RW, Pometta D: The distribution of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:246-252, 1991
37. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:917-921, 1988
38. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
39. Pyörälä K, Pedersen TR, Kjekshus J, for the Scandinavian Simvastatin Survival Study (4S) Group: The effect of cholesterol lowering with Simvastatin on coronary events in diabetic patients with coronary heart disease. Diabetes 44:35A, 1995
40. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica J, Warnold JMO, Wun C-C, Davis BR, Braunwald E, for the CARE trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996